Neurizon Therapeutics Management
Management criteria checks 1/4
Neurizon Therapeutics' CEO is Michael Thurn, appointed in May 2024, has a tenure of less than a year. total yearly compensation is A$415.11K, comprised of 69.4% salary and 30.6% bonuses, including company stock and options. directly owns 0.58% of the company’s shares, worth A$465.48K. The average tenure of the management team and the board of directors is 0.6 years and 0.6 years respectively.
Key information
Michael Thurn
Chief executive officer
AU$415.1k
Total compensation
| CEO salary percentage | 69.4% |
| CEO tenure | less than a year |
| CEO ownership | 0.6% |
| Management average tenure | less than a year |
| Board average tenure | less than a year |
Recent management updates
Recent updates
Here's Why We're Not Too Worried About PharmAust's (ASX:PAA) Cash Burn Situation
Apr 09
Here's Why We're Not At All Concerned With PharmAust's (ASX:PAA) Cash Burn Situation
Mar 31Here's Why PharmAust Limited's (ASX:PAA) CEO Compensation Is The Least Of Shareholders Concerns
Nov 03Is PharmAust (ASX:PAA) In A Good Position To Deliver On Growth Plans?
May 30This Is The Reason Why We Think PharmAust Limited's (ASX:PAA) CEO Might Be Underpaid
Oct 14What Does PharmAust's (ASX:PAA) CEO Pay Reveal?
Feb 14CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | AU$415k | AU$288k | -AU$9m |
Compensation vs Market: Michael's total compensation ($USD259.10K) is about average for companies of similar size in the Australian market ($USD290.06K).
Compensation vs Earnings: Insufficient data to compare Michael's compensation with company performance.
CEO
Michael Thurn
less than a year
Tenure
AU$415,107
Compensation
Dr. Michael Thurn, Ph D., serves as Managing Director, CEO and Director of PharmAust Limit since May 31, 2024. He was Chief Executive Officer of Neurizon Therapeutics Limited (formerly known as PharmAust L...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Director | less than a year | AU$415.11k | 0.58% A$ 465.5k | |
| Chief Operating Officer | less than a year | AU$153.58k | 0.13% A$ 103.1k | |
| Chief Scientific Officer | less than a year | AU$26.16k | no data | |
| General Manager of Epichem Pty Ltd | 2.5yrs | AU$26.69k | no data | |
| Head of Marketing & Corporate Affairs | no data | no data | no data | |
| Head of Chemistry | no data | no data | no data | |
| Head of Production | no data | no data | no data | |
| Head of Manufacturing | less than a year | no data | no data | |
| Company Secretary | less than a year | no data | no data |
0.6yrs
Average Tenure
Experienced Management: NUZ's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Director | less than a year | AU$415.11k | 0.58% A$ 465.5k | |
| Director | less than a year | AU$3.13k | 0.054% A$ 43.4k | |
| Veterinary Clinical Advisory Board Member | 7.2yrs | no data | no data | |
| Veterinary Clinical Advisory Board Chair | 7.2yrs | no data | no data | |
| Veterinary Advisory Board Member | 7yrs | no data | no data | |
| Director | less than a year | AU$10.80k | 2.97% A$ 2.4m | |
| Non-Executive Chairman | less than a year | AU$9.38k | 0.27% A$ 217.1k |
0.6yrs
Average Tenure
Experienced Board: NUZ's board of directors are not considered experienced ( 0.6 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 19:33 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Neurizon Therapeutics Limited is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Stefan Tan | Spark Plus Pte Ltd |